Epidemiological Description of the Kaposi's Disease in France's Southeast

Kaposi's Disease Clinical Trial

— KAPOSI-1  

Official title:

Epidemiological Description of the Kaposi's Disease in France's Southeast

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT03662828
• Other study ID #: KAPOSI-1
• Status: Enrolling by invitation
• Start date: August 1, 2018
• Est. completion date: August 2020

Study information

• Verified date: February 2019
• Source: Direction Centrale du Service de Santé des Armées
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate the prevalence of the Kaposi's disease in France's southeast on 10 years (from 2007 to 2017)

Description:

Kaposi's disease is a multifocal disease with cutaneous expression in more than 95% of cases.

There are 4 forms : Mediterranean, Endemic (Sub-Saharan Africa), iatrogenic and epidemic (HIV) The physiological hypotheses to explain the disease are not clear. A proliferation of immunity cells in blood vessels and also an undetermined role of the human herpes virus 8 (HHV-8) could be involved.

The treatment is complex and not standardized. There are a lot of different treatments.

The purpose of this study is to evaluate the prevalence and described the characteristics and the treatment of the Kaposi's disease in the France's southeast on 10 years, from 2007 to 2017.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 100
• Est. completion date: August 2020
• Est. primary completion date: August 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed patients with a Kaposi's disease by biopsy from January 2007 to December 2017

Exclusion Criteria:

• Opposition to the use of personal data

Related Conditions & MeSH terms

• Kaposi's Disease
• Xeroderma Pigmentosum

Locations

Country	Name	City	State
France	CHI de Fréjus	Fréjus	Var
France	HIA Laveran	Marseille	Bouche Du Rhone
France	Centre Antoine Lacassagne	Nice	Alpes-Maritimes
France	CHU Nice	Nice	Alpes-Maritimes
France	Hôpital d'Instruction des Armées Sainte-Anne	Toulon	Var

Sponsors (1)

Lead Sponsor	Collaborator
Direction Centrale du Service de Santé des Armées

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of Kaposi's disease	Diagnosed patients with biopsy, in France's southeast	10 years (2007-2017)
Secondary	Descriptive analysis of the different form of the Kaposi's disease in the population	Mediterranean form, endemic form, iatrogenic form and epidemic form	10 years (2007-2017)
Secondary	Descriptive analysis of the population : sociodemographic	sociodemographic characteristics	10 years (2007-2017)
Secondary	Descriptive analysis of the population : paraclinical	paraclinical characteristics	10 years (2007-2017)
Secondary	Descriptive analysis of the population : clinical	clinical characteristics	10 years (2007-2017)
Secondary	Descriptive analysis of the population : therapeutic	therapeutic care	10 years (2007-2017)
Secondary	Survival analysis	mortality rate	10 years (2007-2017)